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Abstract
Background: It has been demonstrated in numerous studies that N-terminal pro-B-type
natriuretic peptide (NT-proBNP) is strongly associated with left ventricular ejection fraction
(LVEF), functional capacity (FC), and cardiovascular (CV) mortality in heart failure (HF)
patients. The aim of the present study was to determine the predictive cutoff values of
NT-proBNP for predicting these parameters.
Methods: One hundred HF patients (88 male, 12 female, mean age 53.6 ± 8.9 years) with
left ventricular (LV) systolic dysfunction and impaired exercise capacity were enrolled into the
study. Echocardiographic examination was performed. The NT-proBNP concentration was
measured after resting for 20 min in the supine position. The modified Bruce protocol was
utilized for exercise testing. The patients were followed for between 690 and 840 days (mean
750 ± 30 days) for the occurrence of CV events.
Results: There was a strong negative correlation between NT-proBNP concentration and LVEF
(p < 0.004). It was found that NT-proBNP is a strong predictor of LVEF < 30% (p < 0.001). When
940 pg/mL was accepted as a cutoff value for NT-proBNP for the prediction of an LVEF < 30%,
the sensitivity and the specificity were 89.8% and 71.4%, respectively. NT-proBNP and left atrial
diastolic dimension were the most significant parameters for predicting FC (p < 0.001, each one). An
NT-proBNP cutoff value of 940 pg/mL responded to 78.8% sensitivity and 81% specificity for the
prediction of FC < 5 METs. The observed independent predictors for the CV events were NT-
-proBNP, LV mass index, and resting heart rate (p < 0.001, p = 0.02 and p = 0.006, respectively).
Every 1000 pg/mL elevation in NT-proBNP level resulted in a 27% increase in the occurrence of
CV events (p < 0.006). Moreover, 940 pg/mL NT-proBNP cutoff value revealed a sensitivity and
specificity of 86.7% and 64.7% respectively for the prediction of incident CV events.
Conclusions: Use of NT-proBNP cutoff values is easy and reliable method for the prediction
of low FC and decreased LVEF, and may aid identification of patients at the highest risk for
future CV events. We suggest to use NT-proBNP cutoff value of 940 pg/mL for predicting these
parameters. (Cardiol J 2009; 16: 43–51)
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Introduction
Numerous studies have shown that N-termi-
nal pro-B-type natriuretic peptide (NT-proBNP) is
strongly associated with left ventricular ejection
fraction (LVEF), functional capacity (FC), and car-
diovascular (CV) mortality in patients with heart
failure (HF) [1–6]. In daily practice, the most com-
monly employed parameters for the treatment de-
cision and determining prognosis of HF patients are
FC and LVEF [7]. Although data have accumulated
to demonstrate a strong association between
HF and NT-proBNP, reported values regarding
NT-proBNP have been quite variable, which limits
its clinical use [1–6, 8, 9]. The aim of the present
study was to identify predictive cutoff values of
NT-proBNP for low FC, decreased LVEF, and CV
events in patients with HF. To transform
NT-proBNP into an effective and practical tool, the
present study was held to identify cutoff values for
predicting low FC, decreased LVEF, and future CV
events in patients with HF.
Although NT-proBNP is an effective tool in the
management of HF and data have accumulated to
demonstrate a strong association between HF and
NT-proBNP, its clinical use is relatively limited due
to practical reasons.
Methods
Study group
One hundred HF patients (88 male, 12 female,
mean age 53.6 ± 8.9 years) with left ventricular
(LV) systolic dysfunction were included in this pro-
spective study. We established, as inclusion crite-
ria for our study, significantly depressed LV systo-
lic dysfunction (LVEF < 45%) assessed with echo-
cardiographic examination and impaired exercise
capacity before or at the commencement of study.
Patients with renal failure (creatinine > 2 mg/dL),
chronic obstructive pulmonary disease, atrial and
ventricular arrhythmias, left bundle branch block,
clinical limitations to exercise including symptoma-
tic peripheral vascular disease, a history of recent
acute coronary syndrome, or valvular heart disease
were excluded. After medical history and physical exa-
mination, the subjects were incorporated into four
groups according to New York Heart Association
(NYHA) classification. Patients were in a stable
condition for ≥ 4 weeks before enrolment, and all
were taking either angiotensin converting enzyme
inhibitors or angiotensin receptor blockers. Sixty-
five (65%), 68 (68%), 36 (36%) and 46 (46%) pa-
tients were receiving diuretics, beta-blockers,
digitalis, or spironolactone therapy, respectively.
Twenty-two (22%) patients had a history of coro-
nary artery bypass grafting (CABG) before enrol-
ment into the study. The local ethics committee
approved the study and informed consent was ob-
tained from all subjects. The patients were followed
for between 690 ans 840 days (mean 750 ± 30 days)
for the occurrence of CV events (cardiac death or
hospitalization for decompensated heart failure, acu-
te coronary syndromes, and arrhythmia).
Echocardiographic examinations
All echocardiographic examinations were ob-
tained at rest. Standard echocardiography, pulsed
wave, and tissue Doppler imaging were carried out
using an Acuson Sequoia machine (Acuson Corpora-
tion, Mountain View, California) with a 2.5 or 3.5 MHz
phased array transducer. A single experienced car-
diologist (MK) performed echocardiography and the
mean of three consecutive cycles was used to drive
the analysis. M-mode evaluation was made accor-
ding to the recommendations of the American
Society of Echocardiography [10]. The smallest and
largest images of the LV during systole and diasto-
le were obtained with apical 4-chamber view. The
LVEF was calculated using modified Simpson’s
technique [11]. The LV mass was calculated by
using the Devereux formula [12] and indexed to
body surface area. Pulsed-wave Doppler was asses-
sed by measurement of transmitral flow parameters
including early E and late A diastolic filling veloci-
ties, the E/A ratio, E deceleration, and isovolumic
relaxation times (DT and IVRT), in the apical
4-chamber view. The same measurements were re-
peated during phase II of Valsalva’s manoeuvre.
Diastolic function was classified as follows [13]:
— normal: E/A > 1, DT < 220 ms, IVRT < 100 ms,
E/A > 1 (with Valsalva’s manoeuvre);
— impaired relaxation (mild diastolic dysfunc-
tion): E/A < 1, DT > 220 ms, IVRT > 100 ms;
— pseudonormalization (moderate diastolic dysfunc-
tion): E/A > 1, DT < 220 ms, IVRT < 100 ms,
E/A < 1 (with Valsalva manoeuvre);
— restrictive pattern (severe diastolic dysfunction):
E/A > 2, DT < 150 ms, IVRT < 60 ms.
The velocities of systolic wave Sm and early Em
and late Am diastolic waves were obtained along with
their ratio (Em/Am) at the end of expiration via tis-
sue Doppler examination.
Exercise test
Exercise testing was conducted on a Marquette
2000 treadmill (Marquette Electronics, Milwa-
ukee, USA) by using a modified Bruce protocol.
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Patients with NYHA class IV were excluded from
the test. Electrocardiogram and blood pressure
were monitored throughout. Exercise time, exer-
cise stage, and maximum workload (METs) were
recorded.
Assessment of NT-proBNP
Blood samples were collected to the EDTA-
-containing tubes following 20-minutes of supine
resting. Plasma was extracted after centrifugation
at 3000 rpm for 10 minutes at 0oC. NT-proBNP was
measured within 20 minutes of venipuncture on an
Elecsys 1010 autoanalyser (Roche Diagnostics,
Indianapolis, Indiana) with the use of a commercial
kit (Roche Diagnostics) by electrochemilumine-
scent immunoassay method.
Statistical analysis
All analyses were performed using SPSS ver-
sion 14.0 (SPSS, Inc., Chicago, Illinois). Results for
normally distributed continuous variables are expres-
sed as mean values ± standard deviation (SD),
and continuous variables with non-normal distribu-
tion (NT-proBNP) are presented as median values
(interquartile intervals). NYHA groups were com-
pared by ANOVA or Kruskal-Wallis tests, and for
multiple comparisons Scheffe or Tamhane analyses
were used as post hoc tests. When the dependent
variable was binary, t test or Mann-Whitney tests
were applied. Discrete variables were compared
by c2. Correlations between continuous variables
were assessed using Pearson’s or Spearman’s rank
correlation analysis. Three multivariate logistic
regression analyses were performed to determine
significant predictors for the FC < 5 METs, CV
events, and LVEF < 30%. Significant variables in
univariate analysis at level p < 0.1 were entered in
logistic regression analysis. Additionally, two
linear regression analyses were applied for LVEF
and METs. A receiver-operating characteristic cu-
rve analysis was performed to identify the optimal
cutoff point of NT-proBNP concentration for pre-
dicting LVEF, FC, and CV events. The area under
the curve value was calculated to determine the
accuracy of the test. A value of p < 0.05 was consi-
dered statistically significant.
Results
Age and sex distribution were similar among
the NYHA groups (Table 1). In the study popula-
tion, 88 patients had ischemic and 12 patients had
non-ischemic HF (2 peripartum and 10 idiopathic
cardiomyopathy). There was a decrease in systolic
and diastolic blood pressure and an elevation in
heart rate with increasing severity of NYHA class
(p < 0.001, for each). There was a substantial in-
crease in NT-proBNP concentration with worsening
of NYHA class (p < 0.001), a finding that is consi-
stent regardless of parameters investigated like
age, sex, blood pressure and heart rate (Table 2).
Severity of NYHA class was also associated with
Table 1. Clinical and laboratory variables of the patients.
Variable New York Heart Association classification p
Class I Class II Class III Class IV
(n = 25)  (n = 25)  (n = 25)  (n = 25)
Age (years) 52.5 ± 9.4 54.9 ± 8.5 52.9 ± 8.2 54.2 ± 9.3 0.775
Female/male 2/23 2/23 4/21 4/21 0.273
Body mass index [kg/m2] 26.9±3.7 27.6±4.3§ 24.3±3.8 24.5±3.8 0.005
Ischemic/non-ischemic heart failure 23/2 23/2 21/4 21/4 0.332
Systolic blood pressure [mm Hg] 127.6±14.8†, ‡ 129.0±26.3§, D 106.4±17.1 98.7±11.4 < 0.001
Diastolic blood pressure [mm Hg] 82.6±8.3†, ‡ 79.0±12.9§, D 68.8±9.7 65.4±8.9 < 0.001
Heart rate [bpm] 81.6±6.9‡ 83.4±11.8 89.4±15.4 94.1±16.8 < 0.001
Blood urea nitrogen [mg/dL] 16.5±4.7‡ 19.8±6.9D 26.3±14.1¶ 40.7±18.7 < 0.001
Creatinine [mg/dL] 1.0±0.17‡ 1.1±0.27D 1.2±0.31¶ 1.5±0.38 < 0.001
Sodium [mmol/L] 138.1±3.1†, ‡ 137.9±4.1§, D 133.8±4.0 130.1±6.3 < 0.001
Potassium [mmol/L] 4.6±0.7 4.5±0.3 4.5±0.7 4.8±0.9 0.173
NT-proBNP [pg/mL] 192 716 3317 13275 < 0.001
(137–271)‡  (501–1022)D  (2616–4207)¶  (9236–19079)
Data are expressed as mean ± SD, number or median values (interquartile intervals); †p < 0.05 between patients in NYHA classes I and III; ‡p < 0.05
between patients in NYHA classes I and IV; §p < 0.05 between patients in NYHA classes II and III; Dp < 0.05 between patients in NYHA classes II and IV;
¶p < 0.05 between patients in NYHA classes III and IV
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deterioration in echocardiographic parameters of
systolic and diastolic function (Table 2).
Correlates of NT-proBNP
and left ventricular functions
There was a considerable negative correlation
between NT-proBNP and LVEF (Fig. 1). Multivariate
linear regression analysis showed that NT-proBNP
is the most significant predictor for LVEF (beta =
= –0.336, p < 0.004). The only independent pre-
dictor of the LVEF < 30% was the NT-proBNP
(p < 0.001). Logistic regression analysis revealed
that every 500-pg/mL increase in the concentration
of NT-proBNP was associated with a 14.2% incre-
ase in the risk of having LVEF < 30% (odds ratio
0.852, 95% confidence interval 0.798–0.990). In the
receiver-operating characteristic (ROC) curve ana-
lysis a 940 pg/mL NT-proBNP cutoff value yielded
sensitivity and specificity of 89.8% and 71.4%, respec-
tively, for the prediction of LVEF < 30% (Fig. 2A).
Left ventricular E/A and Em/Am ratios were si-
gnificantly increased with the worsening of NYHA
class. Diastolic dysfunction and restrictive pattern
were detected in 89 (89%) and 36 (36%) patients,
respectively. Severity of diastolic dysfunction was
also markedly related with the increase in NYHA
class (Table 2), and serum NT-proBNP levels incre-
ased significantly with the severity of diastolic dys-
function (p = 0.024). Linear regression analysis sho-
wed that left atrial (LA) end-diastolic dimension and
NT-proBNP are the most significant predictors
for LV E/A (beta = 0.377, p < 0.001 and beta = 265,
p = 0.007, respectively). In the ROC curve analy-
sis a 940 pg/mL NT-proBNP cutoff value yielded
Table 2. Echocardiographic and exercise variables of the patients.
Variable New York Heart Association classification p
Class I Class II Class III Class IV
(n = 25)  (n = 25)  (n = 25)  (n = 25)
Septal wall thickness [mm] 9.8±1.8 9.7±1.8 9.3±1.4 9.7±1.8 0.825
LV posterior wall thickness [mm] 9.4±1.3 9.3±1.2 9.4±1.1 9.6±1.1 0.845
LV end-diastolic dimension [mm] 63.1±6.3†,  ‡ 64.1±6.2§, D 71.8±7.8 71.6±9.2 < 0.001
LV end-systolic dimension [mm] 50.1±7.9†,  ‡ 52.1±7.2§, D 63.1±8.1 61.4±10.8 < 0.001
LV ejection fraction (%) 35.3±5.2†,  ‡ 33.4±6.2§, D 25.8±6.3 29.4±7.5 < 0.001
LV mass index [g/m2] 134±31†, ‡ 136±33§, D 174±32 181±43 < 0.001
LA end-diastolic dimension [mm] 43.8±6.11†, ‡ 47.7±8.0§ 53.7±5.9 51.6±5.5 < 0.001
LA end-systolic dimension [mm] 30.5±5.9† 33.5±7.2 38.6±8.1 38.3±7.1 0.014
LV E/A ratio 0.97±0.79†, ‡ 1.98±1.87 2.41±1.57 2.79±1.05 < 0.001
LV deceleration time [ms] 184±59†, ‡ 159±64 120±54 115±48 < 0.001
LV isovolumic relaxation time [ms] 123±26† 106±39 104±42 96±24 0.032
LV Sm velocity [cm/s] 11±3.1†, ‡ 11±2.8§, D 8.2±1.6 7.6±1.5 < 0.001
LV Em/Am ratio 0.9±0.5†, ‡ 1.4±0.9 1.7±0.9 1.7±1.0 0.007
Normal/mild/moderate/severe 5/16/3/1 3/13/1/8 2/7/3/13 1/5/5/14 < 0.001
diastolic dysfunction (n)
Exercise stage 3.4±0.9*, † 2.0±0.7§ 0.6±0.3 — < 0.001
Exercise time [min] 15±2.3*, † 11±1.5§ 4.6±1.7 — < 0.001
Maximum workload [METs] 11±2.1*, † 6.6±1.7§ 3.0±0.7 — < 0.001
Data are expressed as mean ± SD or numbers; LA — left atrium, LV — left ventricle; *p < 0.05 between patients in NYHA classes I and II; †p < 0.05
between patients in NYHA classes I and III; ‡p < 0.05 between patients in NYHA classes I and IV; §p < 0.05 between patients in NYHA classes II and III;
Dp < 0.05 between patients in NYHA classes II and IV; ¶p < 0.05 between patients in NYHA classes III and IV
Figure 1. The relationship between left ventricular ejec-
tion fraction (LVEF) and N-terminal pro-B-type natriure-
tic peptide (NT-proBNP).
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a sensitivity and specificity of 88.9% and 60.2%,
respectively, for the prediction of restrictive
pattern.
Correlates of NT-proBNP
and functional capacity
A significant negative correlation was found
regarding serum NT-proBNP and exercise time,
exercise stage, and maximum METs value (p < 0.001,
for each). Linear regression analysis showed that
NT-proBNP level and LA diastolic dimension were
the most important predictors of maximum METs va-
lue (beta = –0.478, p < 0.001, beta = –0.359, p = 0001,
respectively) in NYHA I–III patients. Furthermore,
the independent predictors of low FC (< 5 METs)
were NT-proBNP level and LA diastolic dimension
(p = 0.002 and p = 0.049, respectively). Logistic
regression analysis showed that every 500-pg/mL
elevation in NT-proBNP concentration resulted in
a 15.2% increase in the risk of having FC < 5 METs
(odds ratio 1.152, 95% confidence interval 1.051–
–1.262). ROC curve analysis showed that when
940 pg/mL was accepted as a cutoff for NT-proBNP
in the prediction of FC < 5 METs, the sensitivity
and the specificity were 78.8% and 81.0%, respecti-
vely. The area under the curve (AUROC) was
Figure 2. Receiver-operating characteristic curve analysis of (A) NT-proBNP in obtaining ejection fraction < 30%,
(B) NT-proBNP in determining functional capacity < 5 METs, and (C) NT-proBNP in predicting cardiovascular events.
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0.906 (95% confidence interval 0.837–0.975) indi-
cating a good discriminatory power (Fig. 2B).
NT-proBNP and cardiac outcome
During the follow up period, 25 cardiac related
deaths and 21 hospitalizations (14 patients with
decompensated HF, 5 patients with acute coronary
syndromes, and 2 patients with arrhythmia) occur-
red. Two patients with NYHA class IV underwent
cardiac resynchronization therapy for worsening
HF. Significant characteristics of patients with and
without CV events are listed in Table 3. Patients
with high baseline NT-proBNP were more prone
to cardiac events than those with low NT-proBNP.
Multivariate logistic regression analysis demonstra-
ted that independent predictors for CV events were
NT-proBNP, LV mass index, and resting heart
rate (p < 0.001, p = 0.02, and p = 0.006, respecti-
vely). Moreover, every 1000 pg/mL elevation in
NT-proBNP level resulted in a 27% increase in the
occurrence of CV events (odds ratio 1.270, 95%
confidence interval 1.072–1.505) (Table 4).
In the ROC curve analysis a 940 pg/mL NT-proBNP
cutoff value revealed sensitivity and specificity of
86.7% and 64.7%, respectively, for the prediction
of incident CV events. The AUROC in predicting
CV events was found to be 88.8%, 75.0% and 64.9%
for NT-proBNP, LV mass index and resting heart
rate, respectively. The AUROC was calculated at
0.888 (95% confidence interval 0.822–0.955) indi-
cating a good discriminatory power (Fig. 2C).
Discussion
Our study has shown a strong correlation be-
tween NT-proBNP and LVEF, functional capacity,
and CV events in patients with heart failure. Fur-
thermore it can be used as an effective tool for pre-
dicting these parameters. A cutoff NT-proBNP
value of 940 pg/mL is highly predictive for decreased
ejection fraction (LVEF < 30%), low FC (< 5 METs),
and future CV events.
Table 3. Significant variables of the patients with and without cardiovascular events.
Variables Cardiovascular events (+) Cardiovascular events (–) p
 n = 46  n = 54
Systolic blood pressure [mm Hg] 107±22 123±20 0.001
Diastolic blood pressure [mm Hg] 69±11 79±12 < 0.001
Heart rate [bpm] 94±15 81±9 < 0.001
NT-proBNP [pg/mL] 5417 (3655–8029) 496 (337–731) < 0.001
BUN [mg/dL] 33.9±18.7 20.10±8.6 < 0.001
Creatinine [mg/dL] 1.33±0.38 1.07±0.27 0.001
Sodium [mmol/L] 133±5.5 137±4.9 < 0.001
LV end-diastolic dimension [mm] 71.3±8.8 64.2±6.7 < 0.001
LV end-systolic dimension [mm] 61.0±10.4 52.4±8.5 < 0.001
LV end-diastolic volume [mL] 264±68 213±53 0.001
LV end-systolic volume [mL] 187±67 140±52 0.005
LV ejection fraction (%) 25.4±6.6 33.1±6.4 < 0.001
LA end-diastolic dimension [mm] 52.5±7.1 45.9±6.1 < 0.001
LA end-systolic dimension [mm] 43.2±4.4 31.2±5.7 0.01
LV mass index (g/m²) 177.3±40.2 136.7±31.7 < 0.001
LV E/A ratio 2.75±1.30 1.43±1.44 < 0.001
LV Sm velocity [cm/s] 7.4±1.4 10.2±2.9 < 0.001
LV Em/Am ratio 1.79±1.05 1.28±0.80 0.021
Maximum workload [METs] 4.26±2.62 8.12±3.13 < 0.001
Data are expressed as mean ± SD or median values (interquartile intervals); LA — left atrium, LV — left ventricle
Table 4. Multivariate logistic regression analysis
for the prediction of cardiovascular events.
Variable Odds 95% confidence p
ratio interval
NT-pro-BNP 1.270 1.072–1.505 0.006
(1000 pg/mL)
Left ventricular 1.019 1.003–1.036 0.020
mass index [g/m²]
Heart rate [bpm] 1.081 1.023–1.143 0.006
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Previously, numerous studies have demonstra-
ted a strong association between NT-proBNP con-
centration and LV dimensions, volumes, and func-
tions in HF patients [8, 9, 14–16]. The relationship
was also significant in asymptomatic patients and
healthy controls. In a study involving asymptoma-
tic individuals with HF, the sensitivity and specifi-
city of the 33 pmol/L NT-proBNP cutoff value was
84% and 85%, respectively, for predicting LVEF >
> 58% [15]. Kotaska et al. [8] found that the AUROC
in predicting ejection fraction < 40% was 60% and
69% for BNP and NT-proBNP, respectively. In our
study, an NT-proBNP cutoff value of 940 pg/mL re-
vealed a sensitivity and specificity of 89.8% and
71.4%, respectively, for the prediction of LVEF <
< 30%. Restrictive filling pattern in systolic HF pa-
tients was associated with increased NT-proBNP
level, impaired functional capacity and worse pro-
gnosis [17, 18]. Troughton et al. [16] demonstra-
ted that, BNP levels reflect the severity of diasto-
lic abnormality in patients with systolic HF. Our
study is in accordance with previous studies and
a significant positive correlation was found between
NT-proBNP and LV E/A ratio. When 940 pg/mL was
accepted as a cutoff value for NT-proBNP in the pre-
diction of restrictive pattern, the sensitivity and spe-
cificity were 88.9% and 60.2%, respectively.
Several echocardiographic and laboratory pa-
rameters were related with functional capacity in
this study. Among these, NT-proBNP level and LA
end diastolic dimension were the only independent
predictors of FC. In daily practice the NYHA clas-
sification and six-minute walk test are usually the
preferred methods for the evaluation of FC [19, 20].
The NYHA is a subjective classification, depending
on a description of patients’ complaints and the
evaluation of the practitioners [19, 21]. Currently,
maximal oxygen (O2) consumption (VO2max) measure-
ment is the most reliable method in determining FC.
However, METs values obtained during the exerci-
se test are also a valuable method [22, 23]. Passino
et al. [2] suggested that NT-proBNP plasma values
predict FC and ventilator efficiency in HF patients.
In this study, NT-proBNP was an independent pre-
dictor of VO2max, and an NT-proBNP cutoff value of
537 pg/mL was able to discriminate patients with
VO2max < 14 mL/kg/min. In another study, Kallistra-
tos et al. [3] showed that NT-proBNP plasma levels
exceeding 1190 pg/mL showed 83% sensitivity and
86% specificity for detecting VO2max < 14 mL/kg/min,
which was a good indicator of low FC [3]. However,
Hogenhuis et al. [24] observed a weak correlation
between six-minute walk test and serum NT-proBNP
levels. Our finding also confirmed those studies.
We found a negative correlation between NT-proBNP
level and METs, exercise time and exercise stage,
which was in agreement with reports of Passino and
Kallistratos et al. [2, 3]. Additionally, we also de-
monstrated that NT-proBNP levels and LA diasto-
lic dimensions were the independent predictors
of FC < 5 METs. When 940 pg/mL was used as
a cutoff value for NT-proBNP in the prediction of
FC < 5 METs, the sensitivity and the specificity
were 78.8% and 81.0%, respectively.
Our results suggested that NT-proBNP, LV mass
index, and resting heart rate were independent
predictors for future CV events. LVEF is an impor-
tant parameter in predicting survival [7]. Numero-
us studies have shown that serum BNP levels may
predict prognosis better than LVEF [25–27]. We
also found that NT-proBNP level is a more impor-
tant parameter than LVEF in predicting cardiova-
scular events. However, the SOLVD trial showed
that LV mass index was a more important parame-
ter than LVEF in detecting mortality and morbidi-
ty [28].  Our findings are in concordance with the
SOLVD trial. NT-proBNP is also a very important
parameter in predicting mortality and morbidity in
both HF and post myocardial infarction patients [4, 29].
In a study, the AUROC in predicting mortality
was found to be 73.8%, 64%, 65% and 65.4% for
NT-proBNP, LVEF, VO2max and HF survival score, re-
spectively [4]. This finding suggests that NT-proBNP
has the highest diagnostic value for mortality. In our
study, among the parameters analyzed as predic-
tors of CV events, the ROC curve analysis for
NT-proBNP had the highest value. The AUROC
were found to be 88.8%, 75.0% and 64.9% for
NT-proBNP, LV mass index and resting heart rate,
respectively.
There are different cutoff values for BNP me-
asurement in predicting prognosis. This difference
may be due to the different characteristics of the
study population and the use of a different BNP kit
and analyses system. Among these values, the
COPERNICUS trial showed that the combined
1-year risks for all-cause mortality or hospitalization
for HF were 14%, 25.6% or 46.7% in patients with
NT-proBNP levels < 199 pmol/L, 199–504 pmol/L
or > 504 pmol/L, respectively [9]. Bayes-Genis et
al. [5] found that when 908 ng/L was accepted as
a cutoff value for NT-proBNP in the prediction of
sudden cardiac death, the sensitivity and the spe-
cificity were 81% and 55%, respectively. BNP and
NT-proBNP may predict all causes of mortality in
patients admitted to emergency departments [6].
In this study, optimal cutoff level for the predic-
tion of survival was 2060 ng/L for NT-proBNP.
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In a study [30] suggested that a single measurement
of NT-proBNP in patients with advanced chronic HF
can help identify patients with the highest risk of
death. In this study, the median value for NT-proBNP
was 1494 pg/mL. Gardner et al. [4] reported that
a 1490 pg/mL cutoff value for NT-proBNP level  pre-
dicts one-year mortality in NYHA class II–IV patients.
In a recent study the cutoff value for NT-proBNP has
been proposed at 1500 pg/mL as a discriminating
marker of short-term survival [31]. Our cutoff va-
lue was 940 pg/mL for two years CV events, and
confirms previous studies.
Limitations of the study
Our study had some limitations. The sample
size of the study was small, the patients were on
different medications with different dosages, we did
not take the medication into account, which may
have had some influence on the NT-proBNP levels
and the prognosis.
Conclusions
Different cutoff values of NT-proBNP are an
easy and reliable method for the prediction of low
FC and decreased LVEF and can help in the identi-
fication of patients at highest risk of CV events.
However, 940 pg/mL may be used to anticipate de-
creased ejection fraction, low FC, and CV events.
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